04 November 2020 | News
AVATAMED's platform selects the most optimal anti-cancer drugs by utilizing drug screening and genomic data from patient-derived cells
Image source: PR Newswire
AVATAMED, a precision medicine service company based in Singapore, represented by CEO Hong Boon Toh, has entered into a business agreement with Macrogen, a biotechnology company in precision medicine headquartered in South Korea, represented by CEO Sukang Lee, for the purpose of collaborating on personalized precision medicine services in cancer treatment.
In accordance with the business agreement, both companies will collaborate on 3 areas, creating a platform for precision medicine services in cancer treatment leveraging on AVATAMED's drug screening technology and Macrogen's genomic analysis expertise; commercializing this precision medicine services in Southeast Asia and Europe; and implementing the K-BIO infectious disease prevention system.
In offering the precision medicine services, AVATAMED's platform selects the most optimal anti-cancer drugs by utilising drug screening and genomic data from patient-derived cells, while Macrogen analyses the genomic data from the biopsy of cancer patients. Integrating both technologies will be very valuable in selecting personalized treatment for the individual patient, which minimizes side effects and maximizes the treatment efficiency of the drugs.
In addition, both companies will jointly implement the K-BIO infectious disease prevention system business by expanding on Macrogen's COVID-19 Smart Mobile Laboratory (SML) and AVATAMED's Smart Negative Pressure Isolation Room (NPIR) solutions. These mobile laboratories and mobile clinic solutions complement the fight against COVID-19.